Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view

Expert Review of Anticancer Therapy

Volumn 14, Issue 11, 2014, Pages 1283-1294

  Bracarda, Sergio ^a   Sisani, Michele ^a   Marrocolo, Francesca ^a   Hamzaj, Alketa ^a   Del Buono, Sabrina ^a   Altavilla, Amelia ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

abiraterone acetate; androgen deprivation therapy; cabazitaxel; castration resistant prostate cancer; docetaxel; enzalutamide; radium 223; treatment algorithm

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CABOZANTINIB; DOCETAXEL; ENZALUTAMIDE; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ANTIANDROGEN; ANTINEOPLASTIC AGENT; TAXOID; TISSUE EXTRACT;

ANEMIA; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; ALGORITHM; DRUG RESISTANCE; MALE; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ALGORITHMS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TISSUE EXTRACTS;

EID: 84910055519     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.965686     Document Type: Review

References (48)

1. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. TherAdv Med Oncol 2012;4(6):329-40
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009;59: 225-49
3. Gaztañaga M, Crook J. Androgen deprivation therapy: minimizing exposure and mitigating side effects. J Natl Compr Canc Netw 2012;10(9):1088-95
4. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
8. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
9. A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer. Available from: https://clinicaltrials. gov/ct2/results? term=NCT01212991&Search=Search
10. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
11. Saad F. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. TherAdv Urol 2013;5(4):201-10
12. Sweeney C, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 2014;32(5 Suppl):abstract LBA2
13. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
14. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747):1147-54
15. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
16. Bahl A, Masson S, Birtle A, et al. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 2014; 40(1):170-7
17. Heck MM, Thalgott M, Retz M, et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 2012;110:11 Pt B E635-40
18. Yin L, Hu Q. Q CYP17 inhibitors- abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol 2014; 11(1):32-42
19. Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2014;74(4):433-40
20. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983-92
21. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13(12):1210-17
22. Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648-57
23. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24(9):2402-8
24. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013;5:1-14
25. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class apharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012;30(Suppl 5):abstract 8
26. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15:738-46
27. Parker C, Vogelzang NJ, Oliver Sartor A, et al. 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study. J Clin Oncol 2014;32(5 Suppl):abstract 5070
28. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 2011;107(Suppl 2): 13-20
29. Di Lorenzo G, Buonerba C, Faiella A, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011;107:234-9
30. Oudard S, Kramer G, Creppy L, et al. Management of metastatic castrationresistant prostate cancer (mCRPC) After an initial good response to first-line docetaxel (D) - a retrospective study on 270 patients (pts). Eur J Cancer 2011;47(Suppl 1):S499-500; abstract 7049
31. Mountzios I, Bournakis E, Efstathiou E, et al. Intermittent docetaxel chemotherapy in patients with castrate resistant prostate cancer. Urology 2011;77:682-7
32. Eymard J-C, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxelsensitive prostate cancer: a retrospective multicentre study. BJU Int 2010;106L: 974-8
33. Schallier D, Decoster L, Braeckman J, et al. Docetaxel in the Treatment of Metastatic Castrationresistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution. Anticancer Res 2012;32: 633-41
34. Caffo O, Pappagallo G, Brugnara S, et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 2012;79:644-9
35. Loriot Y, Massard C, Gross-Goupil M, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010;46: 1770-2
36. Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer. Available from: https://clinicaltrials.gov/ct2/ results?term=NCT01308567&Search=Search
37. Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01605227&Search=Search
38. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
39. Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013; 19(11):3088-94
40. Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev OncolHematol 2013;87(2):122-31
41. Heidenreich A, Scholz HJ, Rogenhofer S, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2013;63(6):977-82
42. Bracarda S, Gernone A, Gasparro D, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 2014;10(6):975-83
43. Heidenreich A, Bracarda S, Mason M, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer 2014;50(6):1090-9
44. Lee JL, Ahn JH, Choi MK, et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer 2014;110: 2472-8
45. Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802-7
46. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30-6
47. Bracarda S, Sisani M, Del Buono S, et al. Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Biologic tools to personalize treatment in genitourinary cancers. Crit Rev OncolHematol 2012;84(Suppl 1):e42-8
48. Sprenger CC, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 2014;5:207-17